Clinical Trial Update: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas [Phase 1]

View source ↗

Summary

This ClinicalTrials.gov update reports a Phase 1 dose-finding and safety study of CC-220, alone and in combination with an anti-CD20 monoclonal antibody, in rel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• CC-220

Snippet

Sponsor: Celgene | Conditions: Lymphoma | Phase 1 | Status: TERMINATED